Business Combinations (Details Narrative) - USD ($)	Jun. 02, 2025	Oct. 11, 2024	Jun. 30, 2025	Jun. 01, 2025	Dec. 31, 2024
Business Combination [Line Items]
Common stock, par value			$ 0.0001		$ 0.0001
Common stock shares			828,110		124,345
NAYA Therapeutics Inc [Member]
Business Combination [Line Items]
Common stock shares	$ 4,803,175
Five Narrow Lane LP [Member]
Business Combination [Line Items]
Convertible debt		$ 8,575,833
Convertible notes payable		$ 3,934,146
Interest rate		7.00%
Principal balance		$ 3,934,146
Maturity date		Dec. 11, 2025
Five Narrow Lane LP [Member] | Common Stock [Member]
Business Combination [Line Items]
Converted shares to receive		18,598
Series C-2 Convertible Preferred Stock [Member] | Five Narrow Lane LP [Member]
Business Combination [Line Items]
Converted shares to receive		8,576
Conversion of stock description		The Company and FNL have agreed that the Company shall issue to FNL a pre-funded common stock purchase warrant (the “NAYA Acquisition Pre-funded Warrants”) to purchase up to 12,764 shares of the Company’s common stock in lieu of 12,764 shares of the aforementioned common stock. See “Note 12 – Stockholders’ Equity” for additional information on the Series C-2 Preferred
Legacy Naya Merger [Member] | Common Class A [Member]
Business Combination [Line Items]
Common stock, par value		$ 0.000001
Legacy Naya Merger [Member] | Common Class B [Member]
Business Combination [Line Items]
Common stock, par value		$ 0.000001
Legacy Naya Merger [Member] | Common Stock [Member]
Business Combination [Line Items]
Converted shares to receive		3,282
Legacy Naya Merger [Member] | Series C-1 Convertible Preferred Stock [Member]
Business Combination [Line Items]
Converted shares to receive		30,375
NAYA Therapeutics Inc [Member]
Business Combination [Line Items]
Redemption price	$ 113.855837742504
Common stock shares				3,227,813
Preferred stock shares				6,300
Interest rate	7.00%